Can Cell Cycle Protein Prevent or Kill Breast Cancer Tumors?
News Jul 20, 2015
Every parent knows the maxim “feed a cold, starve a fever.” In cancer, however, exactly how to feed or starve a tumor has not been easy to determine.
A study led by scientists at The University of Texas MD Anderson Cancer Centerhas shown that a simple molecule called 14-3-3 sigma could be one answer for explaining cancer metabolism, the chemical process by which a tumor forms, grows or dies.
“We know that all cancers grow by learning how to reprogram their metabolism,” said Mong-Hong Lee, Ph.D., professor of Molecular and Cellular Oncology. “But exactly how this occurs has not been fully understood. Our study showed that 14-3-3 sigma opposes and reverses tumor-promoting metabolic programs.”
Lee’s study results revealed new understanding about how 14-3-3 sigma – a cell cycle “controller” –regulates cancer metabolic programming, thus protecting healthy cells from turning into tumor-producing factories.
In vivo and in vitro experiments showed that, among many biochemical effects, 14-3-3 sigma suppresses cancer glycosis, which prevents cancer’s ability to convert glucose into pyruvate, a substance essential for cell growth.
“14-3-3 sigma expression levels can help predict overall and recurrence-free survival rates, tumor glucose uptake, and metabolic gene expression in breast cancer patients,” said Lee. “These results highlight that 14-3-3 sigma is an important regulator of tumor metabolism, and loss of 14-3-3 sigma expression is critical for cancer metabolic reprogramming.”
Lee believes that the study findings provide additional insight about the “crosstalk” between cancer metabolism and cell cycle.
“We anticipate that pharmacologically elevating 14-3-3 sigma’s function in tumors could be a promising direction for targeted anti-cancer metabolism therapy development in the future,” he said.
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE